Literature DB >> 7934163

The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia.

D W Coghlan1, A A Morley, J P Matthews, J F Bishop.   

Abstract

To determine the incidence and prognostic significance of mutation in the N-ras gene in de novo acute myeloid leukemia (AML) we performed an analysis of bone marrow smears from 219 patients with de novo AML treated between 1984 and 1986 and followed for at least six years. DNA extracted from bone marrow smears taken at diagnosis was screened for the presence of mutations in codons 12 and 13 of exon 1 by using the polymerase chain reaction to insert an Hph1 restriction enzyme site into DNA. Presumptive mutations were confirmed by direct sequencing. Mutations were detected in a total of 26 patients (12%); in nine patients (4%) in codon 12 only, in ten patients (5%) in codon 13 only, and in seven patients (3%) in both codons. Mutations in codon 12 or codon 13 were not associated with any clinical features. Mutations in codon 12 had no prognostic significance but mutations in codon 13 were associated with an increased remission rate, a more durable remission, and a significantly prolonged survival which appeared to be independent of other prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934163

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Hirozumi Sano; Akira Shimada; Tomohiko Taki; Chisato Murata; Myoung-Ja Park; Manabu Sotomatsu; Ken Tabuchi; Akio Tawa; Ryoji Kobayashi; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2012-03-10       Impact factor: 2.490

2.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

Review 3.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

4.  Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.

Authors:  P Y Mak; D H Mak; H Mu; Y Shi; P Ruvolo; V Ruvolo; R Jacamo; J K Burks; W Wei; X Huang; S M Kornblau; M Andreeff; B Z Carter
Journal:  Apoptosis       Date:  2014-04       Impact factor: 4.677

Review 5.  The molecular genetics of hematologic malignancies.

Authors:  A Bagg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

6.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

7.  Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.

Authors:  Gautam Borthakur; Leslie Popplewell; Michael Boyiadzis; James Foran; Uwe Platzbecker; Norbert Vey; Roland B Walter; Rebecca Olin; Azra Raza; Aristoteles Giagounidis; Aref Al-Kali; Elias Jabbour; Tapan Kadia; Guillermo Garcia-Manero; John W Bauman; Yuehui Wu; Yuan Liu; Dan Schramek; Donna S Cox; Paul Wissel; Hagop Kantarjian
Journal:  Cancer       Date:  2016-03-18       Impact factor: 6.860

8.  Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Authors:  Tapan M Kadia; Hagop Kantarjian; Steven Kornblau; Gautam Borthakur; Stefan Faderl; Emil J Freireich; Raja Luthra; Guillermo Garcia-Manero; Sherry Pierce; Jorge Cortes; Farhad Ravandi
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

9.  Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

Authors:  Talha Badar; Keyur P Patel; Philip A Thompson; Courtney DiNardo; Koichi Takahashi; Monica Cabrero; Gautam Borthakur; Jorge Cortes; Marina Konopleva; Tapan Kadia; Zach Bohannan; Sherry Pierce; Elias J Jabbour; Farhad Ravandi; Naval Daver; Raja Luthra; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2015-10-19       Impact factor: 3.156

10.  Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Authors:  Mona Meyer; Daniela Rübsamen; Robert Slany; Thomas Illmer; Kathleen Stabla; Petra Roth; Thorsten Stiewe; Martin Eilers; Andreas Neubauer
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.